Utah Medical Products Inc key statistics and ratios

In fiscal 2025, Utah Medical Products Inc had return on equity of 9.5%, an operating margin of 29.6%, debt equal to 0.2% of equity and a current ratio of 37.62. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Utah Medical Products Inc: financial ratios, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	53.2%	52.6%	59.2%	60.9%	59.9%	60.5%	60.2%	60.3%	63.7%	62.6%	62.8%	60.6%	63.0%	61.6%	59.8%	59.0%	57.1%	57.9%
Operating margin	36.4%	35.5%	31.3%	36.6%	36.6%	39.3%	39.0%	41.2%	45.9%	44.5%	37.6%	32.5%	38.5%	37.9%	33.4%	33.2%	29.6%	28.4%
Net margin	24.1%	23.9%	19.6%	24.5%	28.2%	27.6%	29.5%	30.9%	20.5%	44.2%	31.4%	25.6%	30.1%	31.5%	33.1%	33.9%	29.3%	29.0%
Free-cash-flow margin	26.1%	22.4%	29.4%	32.0%	29.6%	34.6%	33.9%	28.6%	37.0%	39.1%	35.2%	45.7%	42.1%	38.9%	43.1%	35.7%	37.2%	31.7%
Return on equity	—	15.9%	18.9%	22.2%	20.4%	18.2%	17.6%	17.5%	11.5%	22.2%	15.5%	10.6%	14.1%	14.9%	13.7%	11.3%	9.5%	8.7%
Return on assets	—	14.6%	12.6%	13.3%	14.5%	14.1%	14.8%	15.6%	10.1%	19.3%	14.1%	9.7%	13.0%	13.8%	12.8%	10.8%	9.2%	8.5%
Asset turnover	—	0.61	0.64	0.54	0.51	0.51	0.50	0.51	0.49	0.44	0.45	0.38	0.43	0.44	0.39	0.32	0.31	0.29
Current ratio	—	13.21	1.77	2.37	3.19	3.31	8.08	11.41	9.32	11.58	15.92	16.42	19.53	15.09	22.56	25.64	37.62	48.62
Debt to equity	—	3.0%	53.2%	25.5%	15.0%	7.5%	0.0%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	0.2%	0.2%	0.2%
Interest cover (operating income ÷ interest)	184.9x	—	13.8x	23.3x	33.9x	56.1x	—	—	—	—	—	—	—	—	—	—	—	—
Effective tax rate	34.7%	33.5%	33.1%	30.0%	21.2%	28.0%	23.8%	26.1%	55.4%	4.6%	17.7%	22.0%	22.4%	20.3%	17.2%	17.4%	20.0%	18.6%
R&D as % of revenue	1.4%	1.6%	−1.4%	1.4%	1.2%	1.1%	1.3%	1.2%	1.1%	1.1%	1.0%	1.2%	1.1%	0.9%	1.1%	2.0%	1.7%	1.9%
Capital spending as % of revenue	1.8%	6.1%	0.7%	0.6%	0.8%	2.7%	0.4%	8.4%	3.9%	1.0%	1.2%	2.0%	1.1%	1.5%	1.3%	0.6%	1.0%	1.1%
Free cash flow ÷ net income	108.0%	93.5%	150.0%	130.9%	104.9%	125.5%	115.0%	92.6%	180.0%	88.6%	112.1%	178.5%	139.6%	123.5%	130.1%	105.2%	126.9%	109.2%
Dividends ÷ net income	53.3%	100.3%	46.3%	35.0%	32.2%	33.1%	32.5%	32.3%	34.7%	21.7%	27.9%	38.1%	77.5%	19.2%	25.7%	30.7%	35.3%	37.6%
Dividends and buybacks ÷ free cash flow	49.4%	107.2%	30.9%	26.7%	30.7%	26.4%	28.2%	34.9%	19.3%	31.8%	27.3%	57.5%	55.5%	27.8%	19.8%	165.9%	86.2%	50.6%

US$ thousands unless shown otherwise. Fiscal quarters.

Utah Medical Products Inc: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	58.0%	58.1%	57.0%	56.2%	57.1%	58.2%	60.6%	55.8%
Operating margin	33.4%	32.0%	32.5%	32.1%	26.6%	27.0%	29.4%	31.1%
Net margin	35.6%	31.7%	31.3%	30.6%	26.8%	28.4%	29.9%	31.5%
Free-cash-flow margin	37.7%	32.0%	44.1%	28.4%	39.2%	37.2%	34.2%	14.6%
Current ratio	29.59	25.64	22.29	41.87	32.06	37.62	28.64	48.62
Debt to equity	—	0.0%	0.2%	—	—	0.0%	0.2%	0.2%
R&D as % of revenue	1.7%	1.3%	1.6%	1.4%	1.7%	2.3%	1.8%	1.8%
SG&A as % of revenue	22.9%	—	23.0%	22.7%	28.8%	—	29.4%	22.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

7 of 7 checks passed · June 30, 2026

What it owns · $125m

Short-term assets $101mLonger-term assets $24m

What it owes, and who funded it · $125m

Short-term liabilities $2mLonger-term liabilities $0mShareholders' equity $122m

Short-term assets cover short-term liabilities $101m of assets due within a year against $2m of liabilities due within a year.
Short-term assets cover long-term liabilities $101m short-term assets against $469,000 of longer-dated liabilities.
More cash than debt $88m of cash against $195,000 of debt.
Debt below 40% of shareholders' equity Debt is 0% of equity.
Debt burden no higher than five years ago Debt to equity moved from 0% to 0% over five years.
A year's operating cash flow covers at least 20% of debt $12m of operating cash flow against $195,000 of debt.
Operating profit covers interest at least five times over No material interest expense reported.

From Utah Medical Products Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

100 /100

Strong moat

How hard Utah Medical Products's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 20 / 20

Net income has been a median 12.1% of total assets over 10 years.
Pricing power 20 / 20

Gross margin has been a median 61.8%, moving by 2.0 percentage points (standard deviation) across 10 years.
Durability 20 / 20

Operating margin has been a median 36.3%; its worst year was 28.4%.
Cash conversion 20 / 20

Free cash flow was positive in 10 of 10 years, at a median 37.5% of revenue.
Discipline 20 / 20

The diluted share count fell 12.6% over five years; stock-based pay has been a median 0.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ECOR vs UTMD CTSO vs UTMD RVP vs UTMD

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Utah Medical Products Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Utah Medical Products Inc.